G. Pellegriti, F. Frasca, C. Regalbuto, S. Squatrito, R. Vigneri, Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013, 965212 (2013)

L.N. Pontius, T.O. Oyekunle, S.M. Thomas, M.T. Stang, R.P. Scheri, S.A. Roman, J.A. Sosa, Projecting survival in papillary thyroid cancer: a comparison of the seventh and eighth editions of the American Joint Commission on cancer/union for international cancer control staging systems in two contemporary national patient cohorts. Thyroid 27(11), 1408–1416 (2017)

Article  PubMed  PubMed Central  Google Scholar 

E.L. Mazzaferri, Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7(2), 265–271 (1997)

Article  CAS  PubMed  Google Scholar 

J. Jonklaas, N.J. Sarlis, D. Litofsky, K.B. Ain, S.T. Bigos, J.D. Brierley, D.S. Cooper, B.R. Haugen, P.W. Ladenson, J. Magner, J. Robbins, D.S. Ross, M. Skarulis, H.R. Maxon, S.I. Sherman, Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12), 1229–1242 (2006)

Article  PubMed  Google Scholar 

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)

Article  PubMed  PubMed Central  Google Scholar 

F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154(6), 787–803 (2006)

Article  CAS  PubMed  Google Scholar 

F. Pacini, D. Fuhrer, R. Elisei, D. Handkiewicz-Junak, S. Leboulleux, M. Luster, M. Schlumberger, J.W. Smit, 2022 ETA Consensus Statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur. Thyroid J. 11(1), e210046 (2022)

Article  CAS  PubMed  Google Scholar 

Y. Ito, A. Miyauchi, Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr. J. 56(2), 177–192 (2009)

Article  PubMed  Google Scholar 

R.C. Webb, R.S. Howard, A. Stojadinovic, D.Y. Gaitonde, M.K. Wallace, J. Ahmed, H.B. Burch, The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocrinol. Metab. 97(8), 2754–2763 (2012)

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid carcinoma Version, 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (2023)

M. Tuttle, L.F. Morris, B. Haugen, J. Shah, J.A. Sosa, E. Rohren, R.M. Subramaniam, J.L. Hunt, N.D. Perrier, Thyroid-differentiated and anaplastic carcinoma. In: Amin, M.B., Edge, S.B., Greene, F., Byrd, D., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M., Meyer, L.R. (eds.) AJCC Cancer Staging Manual, 8th ed., pp. 873–890. Springer, New York (2017)

S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A.; Berruti, ESMO Guidelines Committee.: thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(12), 1856–1883 (2019)

Article  CAS  PubMed  Google Scholar 

C. Schvartz, F. Bonnetain, S. Dabakuyo, M. Gauthier, A. Cueff, S. Fieffé, J.M. Pochart, I. Cochet, E. Crevisy, A. Dalac, D. Papathanassiou, M. Toubeau, Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J. Clin. Endocrinol. Metab. 97(5), 1526–1535 (2012)

Article  CAS  PubMed  Google Scholar 

J. Jonklaas, D.S. Cooper, K.B. Ain, T. Bigos, J.D. Brierley, B.R. Haugen, P.W. Ladenson, J. Magner, D.S. Ross, M.C. Skarulis, D.L. Steward, H.R. Maxon, S.I. Sherman, National Thyroid Cancer Treatment Cooperative Study Group.: Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20(12), 1423–1424 (2010)

Article  PubMed  Google Scholar 

R.K. Orosco, T. Hussain, J.E. Noel, D.C. Chang, C. Dosiou, E. Mittra, V. Divi, L.A. Orloff, Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr. Relat. Cancer 26(10), 795–802 (2019)

Article  PubMed  PubMed Central  Google Scholar 

S. Leboulleux, C. Bournaud, C.N. Chougnet, S. Zerdoud, B.N. Catargi, C.D. Cao, A. Kelly, M.L. Barge, I. Dygay, P. Vera, D. Rusu, O. Schneegans, D. Benisvy, M. Klein, J. Roux, M.C. Eberle, D. Bastie, C. Nascimento, A.L. Giraudet, N.L. Moullec, S. Bardet, D. Drui, N. Roudaut, Y. Godbert, O. Morel, D. Anne, C. Schwartz, F. Velayoudoum, M.J. Schlumberger, L. Leenhardt, I. Borget, Estimabl2: is there a need for radioiodine ablation in low risk differentiated thyroid cancer (DTC) patients?: Results from the French randomized phase III prospective trial on 776 patients (NCT 01837745). J. Endocr. Soc. 5(Suppl 1), A875 (2021)

Article  PubMed Central  Google Scholar 

L. Lamartina, C. Durante, S. Filetti, D.S. Cooper, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100(5), 1748–1761 (2015)

Article  CAS  PubMed  Google Scholar 

E. Ruel, S. Thomas, M. Dinan, J.M. Perkins, S.A. Roman, J.A. Sosa, Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100(4), 1529–1536 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Wang, J. Zhu, Z. Li, T. Wei, The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer. PLoS One 15(6), e0234843 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Zhao, Y. Gong, Radioactive iodine in low- to intermediate-risk papillary thyroid cancer. Front. Endocrinol. (Lausanne) 13, 960682 (2022)

Article  PubMed  Google Scholar 

K. Han, H.M. Noh, H.M. Jeong, Y.C. Lim, Is postoperative adjuvant radioactive iodine ablation therapy always necessary for intermediate-risk papillary thyroid cancer patients with central neck metastasis? Ann. Surg. Oncol. 28(12), 7533–7544 (2021)

Article  PubMed  Google Scholar 

S.K. Kim, J.W. Woo, J.H. Lee, I. Park, J.H. Choe, J.H. Kim, J.S. Kim, Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. Endocr. Relat. Cancer 23(5), 367–376 (2016)

Article  CAS  PubMed  Google Scholar 

S.M. Seidlin, L.D. Marinelli, E. Oshry, Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J. Am. Med. Assoc. 132(14), 838–847 (1946)

Article  CAS  PubMed  Google Scholar 

S.E. Mayson, C.M. Chan, B.R. Haugen, Tailoring the approach to radioactive iodine treatment in thyroid cancer. Endocr. Relat. Cancer 28(10), T125–T140 (2021)

Article  CAS  PubMed  Google Scholar